Ascendis Pharma A/S (ASND)
| Market Cap | 18.06B |
| Revenue (ttm) | 1.37B +86.1% |
| Net Income | 995.60M |
| EPS | 15.23 |
| Shares Out | 65.60M |
| PE Ratio | 18.08 |
| Forward PE | 30.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 826,058 |
| Open | 267.40 |
| Previous Close | 267.07 |
| Day's Range | 265.62 - 278.56 |
| 52-Week Range | 203.80 - 282.15 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 315.07 (+14.41%) |
| Earnings Date | Nov 12, 2026 |
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $315.07, which is an increase of 14.41% from the latest price.
News
Ascendis Pharma price target raised to $346 from $327 at Wedbush
Wedbush raised the firm’s price target on Ascendis Pharma (ASND) to $346 from $327 and keeps an Outperform rating on the shares. The firm says that the company’s Q3 update…
Ascendis Pharma price target raised to $302 from $273 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Ascendis Pharma (ASND) to $302 from $273 and keeps an Overweight rating on the shares.
Ascendis Pharma price target raised to $356 from $326 at Evercore ISI
Evercore ISI raised the firm’s price target on Ascendis Pharma (ASND) to $356 from $326 and keeps an Outperform rating on the shares.
Ascendis Pharma price target raised to $330 from $326 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Ascendis Pharma (ASND) to $330 from $326 and keeps an Overweight rating on the shares following Q3 results. The…
Ascendis Pharma price target raised to $315 from $269 at UBS
UBS raised the firm’s price target on Ascendis Pharma (ASND) to $315 from $269 and keeps a Buy rating on the shares.
Ascendis Pharma price target raised to $352 from $341 at TD Cowen
TD Cowen raised the firm’s price target on Ascendis Pharma (ASND) to $352 from $341 and keeps a Buy rating on the shares. The firm said Q3 Yorvi just beat…
Ascendis Pharma price target raised to $274 from $268 at Canaccord
Canaccord raised the firm’s price target on Ascendis Pharma (ASND) to $274 from $268 and keeps a Hold rating on the shares. The firm noted 3Q revenue had slight beat…
Ascendis Pharma price target lowered to $335 from $344 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ascendis Pharma (ASND) to $335 from $344 and keeps a Buy rating on the shares following the Q3 report.
Ascendis Pharma reports Q3 EPS EUR 1.71, consensus EUR 1.12
Reports Q3 revenue EUR 369.66M, consensus EUR 364.73M. “By always putting patients first, Ascendis has delivered three consecutive approved rare endocrine therapies that are the foundation of our tran...
Ascendis Pharma Earnings Call Transcript: Q3 2026
Q3 product revenue rose 89% YoY to EUR 366 million, with growth across all three products. FY 2026 operating cash flow guidance is at least EUR 600 million; global expansion and pipeline development underpin long-term revenue targets.
Ascendis Pharma Earnings release: Q3 2026
Ascendis Pharma released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Ascendis Pharma Reports Third Quarter 2026 Financial Results
Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ® , €59 million for SKYTROFA ® , and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions recomm...
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
COPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare...
Ascendis gets COMP opinion for TransCon CNP orphan designation maintenance
Ascendis Pharma (ASND) announced that the Committee for Orphan Medicinal Products, or COMP, of the European Medicines Agency, or EMA, has adopted an opinion recommending maintenance of orphan medicina...
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Med...
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thurs...
Ascendis Pharma announces new data from PaTH Forward, PaTHway trials
Ascendis Pharma (ASND) announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon PTH for up t...
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney func...
Ascendis Pharma initiated with a Hold at Canaccord
Canaccord initiated coverage of Ascendis Pharma (ASND) with a Hold rating and $268 price target The company is executing very well with its rare endocrinology franchise that includes three commercial…
Ascendis Pharma price target lowered to $330 from $360 at Citi
Citi analyst Eric Joseph lowered the firm’s price target on Ascendis Pharma (ASND) to $330 from $360 and keeps a Buy rating on the shares. The firm expects the company’s…
Ascendis gets CHMP opinion recommending marketing authorization for TransCon CNP
Ascendis Pharma (ASND) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted an opinion recommending marketing authorization...
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agenc...
Ascendis Pharma assumed with a Buy at UBS
UBS assumed coverage of Ascendis Pharma (ASND) with a Buy rating with a price target of $269, down from $307. The company’s key drug, Yorvipath for chronic hypoparathyroidism, is on…
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcas...
Ascendis Pharma falls -12.8%
Ascendis Pharma (ASND) is down -12.8%, or -$33.92 to $231.00.